Open Payments

Ascension Seton Medical Center

Type
Teaching hospital
Where
Austin, TX
Medicare CCN
450056
Received
$604,333 in 467 records, 2021 ($26,014 general, $578,319 research)
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2021General payment23$26,014
2021Research payment444$578,319

By company

CompanyRecordsAmountYears
Regeneron Pharmaceuticals, Inc.47$224,8562021
VERTEX PHARMACEUTICALS INCORPORATED6$89,8102021
Abbott Laboratories34$82,4902021
Aimmune Therapeutics, Inc.283$75,3802021
Terumo Medical Corporation2$25,9412021
Boston Scientific Corporation10$20,2352021
Esperion Therapeutics, Inc.51$20,0272021
JAZZ PHARMACEUTICALS INC.1$15,0002021
Travere Therapeutics, Inc.5$14,0952021
AngioDynamics, Inc.1$13,0002021
Medtronic, Inc.2$11,5002021
Merge Healthcare Incorporated16$5,8062021
Mallinckrodt Hospital Products Inc.3$2,6002021
Stryker Corporation2$1,5002021
HEARTFLOW, INC.2$1,0002021
Merit Medical Systems Inc1$1,0002021
UCB SA1$902021

By nature of payment

NatureRecordsAmount
Research payment444$578,319
Education1$13,000
Food and Beverage16$5,806
Charitable Contribution1$5,000
Space rental or facility fees (teaching hospital only)4$1,207
Debt forgiveness1$1,000

Records

DateCompanyAmountNatureFormProductStudyYear
2021-12-31AngioDynamics, Inc.$13,000EducationIn-kind items and servicesSolero Device, Oncology2021
2021-12-31Abbott Laboratories$622Research paymentIn-kind items and servicesHeartMate 3 Left Ventricular Assist Device Device, Heart FailurePHP SHIELD II2021
2021-12-31Aimmune Therapeutics, Inc.$21Research paymentCash or cash equivalentPALFORZIA Biological, ALLERGYA MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS 2021
2021-12-27Esperion Therapeutics, Inc.$96Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2021
2021-12-27Esperion Therapeutics, Inc.$2Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2021
2021-12-16Regeneron Pharmaceuticals, Inc.$3,272Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYAN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA2021
2021-12-15Esperion Therapeutics, Inc.$688Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2021
2021-12-15Esperion Therapeutics, Inc.$539Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2021
2021-12-15Esperion Therapeutics, Inc.$539Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2021
2021-12-10Abbott Laboratories$269Space rental or facility fees (teaching hospital only)Cash or cash equivalent2021
2021-12-09Esperion Therapeutics, Inc.$1Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2021
2021-12-08Abbott Laboratories$1,104Research paymentCash or cash equivalentConfirm Rx Device, Cardiac Rhythm ManagementConfirm Rx Insertable Cardiac Monitor SMART Registry2021
2021-12-08Aimmune Therapeutics, Inc.$2Research paymentCash or cash equivalentA MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS 2021
2021-12-06Boston Scientific Corporation$1,033Research paymentCash or cash equivalentDESBTK Device, Clinical Trial ProductHI PEITHO2021
2021-12-06Boston Scientific Corporation$940Research paymentCash or cash equivalentDESBTK Device, Clinical Trial ProductHI PEITHO2021
2021-12-06Boston Scientific Corporation$500Research paymentCash or cash equivalentDESBTK Device, Clinical Trial ProductHI PEITHO2021
2021-12-01Aimmune Therapeutics, Inc.$1,147Research paymentCash or cash equivalentA MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS 2021
2021-12-01Aimmune Therapeutics, Inc.$90Research paymentCash or cash equivalentA MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS 2021
2021-11-26Abbott Laboratories$5,000Research paymentCash or cash equivalentXience Sierra Coronary Stent Device, Vascular15mm Surgical Mechanical Aortic Valve PAS2021
2021-11-22Esperion Therapeutics, Inc.$688Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2021
2021-11-22Esperion Therapeutics, Inc.$194Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2021
2021-11-22Esperion Therapeutics, Inc.$194Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2021
2021-11-18Regeneron Pharmaceuticals, Inc.$13,785Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYA PHASE 2/3 STUDY INVESTIGATING THE PHARMACOKINETICS, SAFETY, AND EFFICACY OF DUPILUMAB IN PATIENTS AGED >=6 MONTHS TO <2021
2021-11-17Medtronic, Inc.$11,000Research paymentCash or cash equivalentFlowMet-R Device, Intraprocedural MonitoringFlowMet-R for PAD and CLI2021
2021-11-17Aimmune Therapeutics, Inc.$528Research paymentCash or cash equivalentA MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS 2021
2021-11-17Medtronic, Inc.$500Research paymentCash or cash equivalentFlowMet-R Device, Intraprocedural MonitoringFlowMet-R for PAD and CLI2021
2021-11-15Aimmune Therapeutics, Inc.$90Research paymentCash or cash equivalentA MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS 2021
2021-11-15Aimmune Therapeutics, Inc.$3Research paymentCash or cash equivalentA MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS 2021
2021-11-10Abbott Laboratories$8,606Research paymentCash or cash equivalentXience Sierra Coronary Stent Device, VascularAMPLATZER PFO Occluder Post Approval Study2021
2021-11-10Aimmune Therapeutics, Inc.$555Research paymentCash or cash equivalentA MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS 2021
2021-11-10Aimmune Therapeutics, Inc.$20Research paymentCash or cash equivalentA MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS 2021
2021-11-05Aimmune Therapeutics, Inc.$4,404Research paymentCash or cash equivalentA MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS 2021
2021-11-04Abbott Laboratories$2,800Research paymentCash or cash equivalentCardioMEMS HF System Device, Heart FailureHemodynamic Guided Monitoring in Heart Failure (HF) Trial2021
2021-11-04Travere Therapeutics, Inc.$1,200Research paymentCash or cash equivalentChenodal Drug, HepatologyA PHASE 3 STUDY TO EVALUATE THE EFFECTS OF CHENODAL IN ADULT AND PEDIATRIC PATIENTS WITH CEREBROTENDINOUS XANTHOMATOSIS2021
2021-11-04Travere Therapeutics, Inc.$1,200Research paymentCash or cash equivalentChenodal Drug, HepatologyA PHASE 3 STUDY TO EVALUATE THE EFFECTS OF CHENODAL IN ADULT AND PEDIATRIC PATIENTS WITH CEREBROTENDINOUS XANTHOMATOSIS2021
2021-11-04Travere Therapeutics, Inc.$590Research paymentCash or cash equivalentChenodal Drug, HepatologyA PHASE 3 STUDY TO EVALUATE THE EFFECTS OF CHENODAL IN ADULT AND PEDIATRIC PATIENTS WITH CEREBROTENDINOUS XANTHOMATOSIS2021
2021-11-03Regeneron Pharmaceuticals, Inc.$6,196Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYAN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA2021
2021-11-03Aimmune Therapeutics, Inc.$975Research paymentCash or cash equivalentA MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS 2021
2021-11-01Aimmune Therapeutics, Inc.$884Research paymentCash or cash equivalentA MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS 2021
2021-11-01Aimmune Therapeutics, Inc.$555Research paymentCash or cash equivalentA MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS 2021
2021-11-01Boston Scientific Corporation$40Research paymentCash or cash equivalentResonate Device, TachyPREEMPT HF2021
2021-11-01Aimmune Therapeutics, Inc.$20Research paymentCash or cash equivalentA MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS 2021
2021-11-01Aimmune Therapeutics, Inc.$2Research paymentCash or cash equivalentA MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS 2021
2021-10-28Abbott Laboratories$625Research paymentCash or cash equivalentDragonfly OCT Device, VascularSupporting Patients Undergoing HIgh-Risk PCI Using a High-Flow Percutaneous Left Ventricular Support Device (SHIELD II)2021
2021-10-25Abbott Laboratories$105Research paymentIn-kind items and servicesConfirm Rx Device, Cardiac Rhythm ManagementConfirm Rx Insertable Cardiac Monitor SMART Registry2021
2021-10-21Esperion Therapeutics, Inc.$539Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2021
2021-10-21Esperion Therapeutics, Inc.$539Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2021
2021-10-21Esperion Therapeutics, Inc.$194Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2021
2021-10-21Esperion Therapeutics, Inc.$194Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2021
2021-10-21Esperion Therapeutics, Inc.$194Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2021
2021-10-20Abbott Laboratories$4,040Research paymentCash or cash equivalentCardioMEMS HF System Device, Heart FailureHemodynamic Guided Monitoring in Heart Failure (HF) Trial2021
2021-10-18Boston Scientific Corporation$276Research paymentCash or cash equivalentDESBTK Device, Clinical Trial ProductHI PEITHO2021
2021-10-18Boston Scientific Corporation$200Research paymentCash or cash equivalentDESBTK Device, Clinical Trial ProductHI PEITHO2021
2021-10-13Regeneron Pharmaceuticals, Inc.$2,508Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYAN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA2021
2021-10-12Esperion Therapeutics, Inc.$800Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2021
2021-10-12Merge Healthcare Incorporated$164Food and BeverageCash or cash equivalentcardio Device, Medical Imaging2021
2021-10-12Esperion Therapeutics, Inc.$3Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2021
2021-10-10Regeneron Pharmaceuticals, Inc.$38Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYAN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA2021
2021-10-08Abbott Laboratories$2,412Research paymentCash or cash equivalentAbsorb GT1 Device, VascularA Clinical Evaluation of Absorb BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects2021
2021-09-30Regeneron Pharmaceuticals, Inc.$4,383Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYAN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA2021
2021-09-28Aimmune Therapeutics, Inc.$1,200Research paymentCash or cash equivalentPALFORZIA Biological, ALLERGYA MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS 2021
2021-09-28Merge Healthcare Incorporated$306Food and BeverageCash or cash equivalentcardiology Device, Medical Imaging2021
2021-09-28Aimmune Therapeutics, Inc.$1Research paymentCash or cash equivalentPALFORZIA Biological, ALLERGYA MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS 2021
2021-09-27Esperion Therapeutics, Inc.$4,000Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2021
2021-09-27Esperion Therapeutics, Inc.$250Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2021
2021-09-23UCB SA$90Research paymentCash or cash equivalentA RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO- AND ACTIVE-CONTROLLED, DOSE FINDING STUDY TO EVALUATE THE EFFICACY AN2021
2021-09-22Regeneron Pharmaceuticals, Inc.$45,543Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYAN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA2021
2021-09-17Abbott Laboratories$269Space rental or facility fees (teaching hospital only)Cash or cash equivalent2021
2021-09-08Abbott Laboratories$1,451Research paymentCash or cash equivalentConfirm Rx Device, Cardiac Rhythm ManagementConfirm Rx Insertable Cardiac Monitor SMART Registry2021
2021-09-08Merge Healthcare Incorporated$73Food and BeverageCash or cash equivalentcardio Device, Medical Imaging2021
2021-09-07Aimmune Therapeutics, Inc.$849Research paymentCash or cash equivalentPALFORZIA Biological, ALLERGYA MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS 2021
2021-09-07Merge Healthcare Incorporated$573Food and Beverage (4 payments)Cash or cash equivalentcardiology Device, Medical Imaging2021
2021-09-07Aimmune Therapeutics, Inc.$1Research paymentCash or cash equivalentPALFORZIA Biological, ALLERGYA MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS 2021
2021-09-07Aimmune Therapeutics, Inc.$1Research paymentCash or cash equivalentPALFORZIA Biological, ALLERGYA MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS 2021
2021-09-07Aimmune Therapeutics, Inc.$1Research paymentCash or cash equivalentPALFORZIA Biological, ALLERGYA MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS 2021
2021-09-07Aimmune Therapeutics, Inc.$1Research paymentCash or cash equivalentPALFORZIA Biological, ALLERGYA MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS 2021
2021-09-07Aimmune Therapeutics, Inc.$1Research paymentCash or cash equivalentPALFORZIA Biological, ALLERGYA MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS 2021
2021-09-01Esperion Therapeutics, Inc.$1,200Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2021
2021-08-25Abbott Laboratories$3,678Research paymentCash or cash equivalentCardioMEMS HF System Device, Heart FailureHemodynamic Guided Monitoring in Heart Failure (HF) Trial2021
2021-08-24Aimmune Therapeutics, Inc.$1,200Research paymentCash or cash equivalentPALFORZIA Biological, ALLERGYA MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS 2021
2021-08-24Aimmune Therapeutics, Inc.$1,200Research paymentCash or cash equivalentPALFORZIA Biological, ALLERGYA MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS 2021
2021-08-24Aimmune Therapeutics, Inc.$1,200Research paymentCash or cash equivalentPALFORZIA Biological, ALLERGYA MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS 2021
2021-08-24Aimmune Therapeutics, Inc.$791Research paymentCash or cash equivalentPALFORZIA Biological, ALLERGYA MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS 2021
2021-08-24Aimmune Therapeutics, Inc.$791Research paymentCash or cash equivalentPALFORZIA Biological, ALLERGYA MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS 2021
2021-08-24Aimmune Therapeutics, Inc.$30Research paymentCash or cash equivalentPALFORZIA Biological, ALLERGYA MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS 2021
2021-08-24Aimmune Therapeutics, Inc.$30Research paymentCash or cash equivalentPALFORZIA Biological, ALLERGYA MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS 2021
2021-08-18Esperion Therapeutics, Inc.$32Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2021
2021-08-15Terumo Medical Corporation$19,941Research paymentCash or cash equivalentPROSPECTIVE, MULTI-CENTER, OBSERVATIONAL, POST-MARKET STUDY TO ASSESS THE SAFETY AND PROCEDURAL SUCCESS OF PERFORMING TR2021
2021-08-12Abbott Laboratories$150Research paymentCash or cash equivalentDragonfly OCT Device, VascularSupporting Patients Undergoing HIgh-Risk PCI Using a High-Flow Percutaneous Left Ventricular Support Device (SHIELD II)2021
2021-08-11Abbott Laboratories$5,048Research paymentCash or cash equivalentMitraClip System Device, Structural HeartAMPLATZER PFO Occluder Post Approval Study2021
2021-08-11Aimmune Therapeutics, Inc.$1,198Research paymentCash or cash equivalentPALFORZIA Biological, ALLERGYA MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS 2021
2021-08-11Esperion Therapeutics, Inc.$1Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2021
2021-08-03Boston Scientific Corporation$3,420Research paymentCash or cash equivalentResonate Device, TachyPREEMPT HF2021
2021-08-03Aimmune Therapeutics, Inc.$955Research paymentCash or cash equivalentPALFORZIA Biological, ALLERGYA MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS 2021
2021-08-03Aimmune Therapeutics, Inc.$87Research paymentCash or cash equivalentPALFORZIA Biological, ALLERGYA MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS 2021
2021-08-03Aimmune Therapeutics, Inc.$30Research paymentCash or cash equivalentPALFORZIA Biological, ALLERGYA MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS 2021
2021-08-03Aimmune Therapeutics, Inc.$30Research paymentCash or cash equivalentPALFORZIA Biological, ALLERGYA MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS 2021
2021-08-03Aimmune Therapeutics, Inc.$1Research paymentCash or cash equivalentPALFORZIA Biological, ALLERGYA MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS 2021
2021-08-03Aimmune Therapeutics, Inc.$1Research paymentCash or cash equivalentPALFORZIA Biological, ALLERGYA MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS 2021
2021-08-03Aimmune Therapeutics, Inc.$1Research paymentCash or cash equivalentPALFORZIA Biological, ALLERGYA MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS 2021
2021-07-28Regeneron Pharmaceuticals, Inc.$1,500Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYA PHASE 2/3 STUDY INVESTIGATING THE PHARMACOKINETICS, SAFETY, AND EFFICACY OF DUPILUMAB IN PATIENTS AGED >=6 MONTHS TO <2021
2021-07-28Regeneron Pharmaceuticals, Inc.$128Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYA PHASE 2/3 STUDY INVESTIGATING THE PHARMACOKINETICS, SAFETY, AND EFFICACY OF DUPILUMAB IN PATIENTS AGED >=6 MONTHS TO <2021
2021-07-22Esperion Therapeutics, Inc.$90Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2021
2021-07-21Abbott Laboratories$399Space rental or facility fees (teaching hospital only)Cash or cash equivalent2021
2021-07-20Esperion Therapeutics, Inc.$194Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2021
2021-07-06Boston Scientific Corporation$1,000Research paymentCash or cash equivalentResonate Device, TachyPREEMPT HF2021
2021-07-06VERTEX PHARMACEUTICALS INCORPORATED$800Research paymentCash or cash equivalentA Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of VX-661/Ivacaftor in Pediatric Subjects With Cystic2021
2021-07-06Boston Scientific Corporation$90Research paymentCash or cash equivalentResonate Device, TachyPREEMPT HF2021
2021-07-01Mallinckrodt Hospital Products Inc.$500Research paymentCash or cash equivalentAN OPEN LABEL EXPANDED ACCESS TREATMENT PROTOCOL FOR VTS-270 (2-HYDROXYPROPYL-CYCLODEXTRIN) IN PATIENTS WITH NEUROLOGIC 2021
2021-06-30Travere Therapeutics, Inc.$10,625Research paymentCash or cash equivalentChenodal Drug, HepatologyA PHASE 3 STUDY TO EVALUATE THE EFFECTS OF CHENODAL IN ADULT AND PEDIATRIC PATIENTS WITH CEREBROTENDINOUS XANTHOMATOSIS2021
2021-06-23Regeneron Pharmaceuticals, Inc.$621Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYA PHASE 2/3 STUDY INVESTIGATING THE PHARMACOKINETICS, SAFETY, AND EFFICACY OF DUPILUMAB IN PATIENTS AGED >=6 MONTHS TO <2021
2021-06-23Regeneron Pharmaceuticals, Inc.$621Research paymentCash or cash equivalentDUPIXENT Biological, INFLAMMATION AND IMMUNOLOGYA PHASE 2/3 STUDY INVESTIGATING THE PHARMACOKINETICS, SAFETY, AND EFFICACY OF DUPILUMAB IN PATIENTS AGED >=6 MONTHS TO <2021
2021-06-23Merge Healthcare Incorporated$218Food and BeverageCash or cash equivalentiCEA Device, Medical Imaging2021
2021-06-22Aimmune Therapeutics, Inc.$6,520Research paymentCash or cash equivalentPALFORZIA Biological, ALLERGYA MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS 2021
2021-06-22Aimmune Therapeutics, Inc.$1,223Research paymentCash or cash equivalentPALFORZIA Biological, ALLERGYA MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS 2021
2021-06-22Aimmune Therapeutics, Inc.$1,200Research paymentCash or cash equivalentPALFORZIA Biological, ALLERGYA MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS 2021
2021-06-22Aimmune Therapeutics, Inc.$1,200Research paymentCash or cash equivalentPALFORZIA Biological, ALLERGYA MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS 2021
2021-06-22Aimmune Therapeutics, Inc.$1,152Research paymentCash or cash equivalentPALFORZIA Biological, ALLERGYA MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS 2021
2021-06-22Aimmune Therapeutics, Inc.$1,093Research paymentCash or cash equivalentPALFORZIA Biological, ALLERGYA MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS 2021
2021-06-22Aimmune Therapeutics, Inc.$1,093Research paymentCash or cash equivalentPALFORZIA Biological, ALLERGYA MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS 2021
2021-06-22Aimmune Therapeutics, Inc.$1,059Research paymentCash or cash equivalentPALFORZIA Biological, ALLERGYA MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS 2021
2021-06-22Aimmune Therapeutics, Inc.$1,059Research paymentCash or cash equivalentPALFORZIA Biological, ALLERGYA MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS 2021
2021-06-22Aimmune Therapeutics, Inc.$1,053Research paymentCash or cash equivalentPALFORZIA Biological, ALLERGYA MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS 2021
2021-06-22Aimmune Therapeutics, Inc.$1,028Research paymentCash or cash equivalentPALFORZIA Biological, ALLERGYA MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS 2021
2021-06-22Aimmune Therapeutics, Inc.$1,028Research paymentCash or cash equivalentPALFORZIA Biological, ALLERGYA MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS 2021
2021-06-22Aimmune Therapeutics, Inc.$998Research paymentCash or cash equivalentPALFORZIA Biological, ALLERGYA MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS 2021
2021-06-22Aimmune Therapeutics, Inc.$998Research paymentCash or cash equivalentPALFORZIA Biological, ALLERGYA MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS 2021
2021-06-22Aimmune Therapeutics, Inc.$916Research paymentCash or cash equivalentPALFORZIA Biological, ALLERGYA MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS 2021
2021-06-22Aimmune Therapeutics, Inc.$796Research paymentCash or cash equivalentPALFORZIA Biological, ALLERGYA MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS 2021
2021-06-22Aimmune Therapeutics, Inc.$779Research paymentCash or cash equivalentPALFORZIA Biological, ALLERGYA MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS 2021
2021-06-22Aimmune Therapeutics, Inc.$779Research paymentCash or cash equivalentPALFORZIA Biological, ALLERGYA MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS 2021
2021-06-22Aimmune Therapeutics, Inc.$779Research paymentCash or cash equivalentPALFORZIA Biological, ALLERGYA MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS 2021
2021-06-22Aimmune Therapeutics, Inc.$742Research paymentCash or cash equivalentPALFORZIA Biological, ALLERGYA MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS 2021
2021-06-22Aimmune Therapeutics, Inc.$737Research paymentCash or cash equivalentPALFORZIA Biological, ALLERGYA MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS 2021
2021-06-22Aimmune Therapeutics, Inc.$706Research paymentCash or cash equivalentPALFORZIA Biological, ALLERGYA MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS 2021
2021-06-22Aimmune Therapeutics, Inc.$706Research paymentCash or cash equivalentPALFORZIA Biological, ALLERGYA MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS 2021
2021-06-22Aimmune Therapeutics, Inc.$706Research paymentCash or cash equivalentPALFORZIA Biological, ALLERGYA MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS 2021
2021-06-22Aimmune Therapeutics, Inc.$688Research paymentCash or cash equivalentPALFORZIA Biological, ALLERGYA MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS 2021
2021-06-22Esperion Therapeutics, Inc.$688Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2021
2021-06-22Esperion Therapeutics, Inc.$688Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2021
2021-06-22Aimmune Therapeutics, Inc.$682Research paymentCash or cash equivalentPALFORZIA Biological, ALLERGYA MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS 2021
2021-06-22Aimmune Therapeutics, Inc.$679Research paymentCash or cash equivalentPALFORZIA Biological, ALLERGYA MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS 2021
2021-06-22Aimmune Therapeutics, Inc.$652Research paymentCash or cash equivalentPALFORZIA Biological, ALLERGYA MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS 2021
2021-06-22Aimmune Therapeutics, Inc.$652Research paymentCash or cash equivalentPALFORZIA Biological, ALLERGYA MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS 2021
2021-06-22Aimmune Therapeutics, Inc.$652Research paymentCash or cash equivalentPALFORZIA Biological, ALLERGYA MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS 2021
2021-06-22Aimmune Therapeutics, Inc.$633Research paymentCash or cash equivalentPALFORZIA Biological, ALLERGYA MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS 2021
2021-06-22Aimmune Therapeutics, Inc.$597Research paymentCash or cash equivalentPALFORZIA Biological, ALLERGYA MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS 2021
2021-06-22Aimmune Therapeutics, Inc.$448Research paymentCash or cash equivalentPALFORZIA Biological, ALLERGYA MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS 2021
2021-06-22Aimmune Therapeutics, Inc.$360Research paymentCash or cash equivalentPALFORZIA Biological, ALLERGYA MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS 2021
2021-06-22Aimmune Therapeutics, Inc.$348Research paymentCash or cash equivalentPALFORZIA Biological, ALLERGYA MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS 2021
2021-06-22Aimmune Therapeutics, Inc.$337Research paymentCash or cash equivalentPALFORZIA Biological, ALLERGYA MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS 2021
2021-06-22Aimmune Therapeutics, Inc.$291Research paymentCash or cash equivalentPALFORZIA Biological, ALLERGYA MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS 2021
2021-06-22Aimmune Therapeutics, Inc.$291Research paymentCash or cash equivalentPALFORZIA Biological, ALLERGYA MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS 2021
2021-06-22Aimmune Therapeutics, Inc.$291Research paymentCash or cash equivalentPALFORZIA Biological, ALLERGYA MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS 2021
2021-06-22Aimmune Therapeutics, Inc.$277Research paymentCash or cash equivalentPALFORZIA Biological, ALLERGYA MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS 2021
2021-06-22Aimmune Therapeutics, Inc.$243Research paymentCash or cash equivalentPALFORZIA Biological, ALLERGYA MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS 2021
2021-06-22Aimmune Therapeutics, Inc.$202Research paymentCash or cash equivalentPALFORZIA Biological, ALLERGYA MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS 2021
2021-06-22Aimmune Therapeutics, Inc.$202Research paymentCash or cash equivalentPALFORZIA Biological, ALLERGYA MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS 2021
2021-06-22Aimmune Therapeutics, Inc.$202Research paymentCash or cash equivalentPALFORZIA Biological, ALLERGYA MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS 2021
2021-06-22Aimmune Therapeutics, Inc.$202Research paymentCash or cash equivalentPALFORZIA Biological, ALLERGYA MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS 2021
2021-06-22Aimmune Therapeutics, Inc.$202Research paymentCash or cash equivalentPALFORZIA Biological, ALLERGYA MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS 2021
2021-06-22Aimmune Therapeutics, Inc.$202Research paymentCash or cash equivalentPALFORZIA Biological, ALLERGYA MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS 2021
2021-06-22Aimmune Therapeutics, Inc.$202Research paymentCash or cash equivalentPALFORZIA Biological, ALLERGYA MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS 2021
2021-06-22Aimmune Therapeutics, Inc.$202Research paymentCash or cash equivalentPALFORZIA Biological, ALLERGYA MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS 2021
2021-06-22Aimmune Therapeutics, Inc.$202Research paymentCash or cash equivalentPALFORZIA Biological, ALLERGYA MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS 2021
2021-06-22Aimmune Therapeutics, Inc.$202Research paymentCash or cash equivalentPALFORZIA Biological, ALLERGYA MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS 2021
2021-06-22Aimmune Therapeutics, Inc.$202Research paymentCash or cash equivalentPALFORZIA Biological, ALLERGYA MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS 2021
2021-06-22Aimmune Therapeutics, Inc.$202Research paymentCash or cash equivalentPALFORZIA Biological, ALLERGYA MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS 2021
2021-06-22Aimmune Therapeutics, Inc.$202Research paymentCash or cash equivalentPALFORZIA Biological, ALLERGYA MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS 2021
2021-06-22Esperion Therapeutics, Inc.$194Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2021
2021-06-22Esperion Therapeutics, Inc.$194Research paymentCash or cash equivalentNEXLETOL Drug, ANTILIPEMIC AGENTSA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC2021
2021-06-22Aimmune Therapeutics, Inc.$180Research paymentCash or cash equivalentPALFORZIA Biological, ALLERGYA MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS 2021
2021-06-22Aimmune Therapeutics, Inc.$177Research paymentCash or cash equivalentPALFORZIA Biological, ALLERGYA MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS 2021
2021-06-22Aimmune Therapeutics, Inc.$121Research paymentCash or cash equivalentPALFORZIA Biological, ALLERGYA MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS 2021
2021-06-22Aimmune Therapeutics, Inc.$121Research paymentCash or cash equivalentPALFORZIA Biological, ALLERGYA MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS 2021
2021-06-22Aimmune Therapeutics, Inc.$121Research paymentCash or cash equivalentPALFORZIA Biological, ALLERGYA MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS 2021
2021-06-22Aimmune Therapeutics, Inc.$121Research paymentCash or cash equivalentPALFORZIA Biological, ALLERGYA MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS 2021
2021-06-22Aimmune Therapeutics, Inc.$121Research paymentCash or cash equivalentPALFORZIA Biological, ALLERGYA MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS 2021
2021-06-22Aimmune Therapeutics, Inc.$121Research paymentCash or cash equivalentPALFORZIA Biological, ALLERGYA MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS 2021
2021-06-22Aimmune Therapeutics, Inc.$121Research paymentCash or cash equivalentPALFORZIA Biological, ALLERGYA MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS 2021
2021-06-22Aimmune Therapeutics, Inc.$121Research paymentCash or cash equivalentPALFORZIA Biological, ALLERGYA MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS 2021
2021-06-22Aimmune Therapeutics, Inc.$121Research paymentCash or cash equivalentPALFORZIA Biological, ALLERGYA MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS 2021
2021-06-22Aimmune Therapeutics, Inc.$121Research paymentCash or cash equivalentPALFORZIA Biological, ALLERGYA MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS 2021
2021-06-22Aimmune Therapeutics, Inc.$121Research paymentCash or cash equivalentPALFORZIA Biological, ALLERGYA MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS 2021
2021-06-22Aimmune Therapeutics, Inc.$121Research paymentCash or cash equivalentPALFORZIA Biological, ALLERGYA MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS 2021
2021-06-22Aimmune Therapeutics, Inc.$121Research paymentCash or cash equivalentPALFORZIA Biological, ALLERGYA MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS 2021
2021-06-22Aimmune Therapeutics, Inc.$121Research paymentCash or cash equivalentPALFORZIA Biological, ALLERGYA MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS 2021
2021-06-22Aimmune Therapeutics, Inc.$109Research paymentCash or cash equivalentPALFORZIA Biological, ALLERGYA MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS 2021
2021-06-22Aimmune Therapeutics, Inc.$109Research paymentCash or cash equivalentPALFORZIA Biological, ALLERGYA MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS 2021
2021-06-22Aimmune Therapeutics, Inc.$109Research paymentCash or cash equivalentPALFORZIA Biological, ALLERGYA MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS 2021
2021-06-22Aimmune Therapeutics, Inc.$109Research paymentCash or cash equivalentPALFORZIA Biological, ALLERGYA MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS 2021
2021-06-22Aimmune Therapeutics, Inc.$109Research paymentCash or cash equivalentPALFORZIA Biological, ALLERGYA MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS 2021
2021-06-22Aimmune Therapeutics, Inc.$109Research paymentCash or cash equivalentPALFORZIA Biological, ALLERGYA MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS 2021
2021-06-22Aimmune Therapeutics, Inc.$109Research paymentCash or cash equivalentPALFORZIA Biological, ALLERGYA MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS 2021
2021-06-22Aimmune Therapeutics, Inc.$109Research paymentCash or cash equivalentPALFORZIA Biological, ALLERGYA MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS 2021
2021-06-22Aimmune Therapeutics, Inc.$109Research paymentCash or cash equivalentPALFORZIA Biological, ALLERGYA MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS 2021
2021-06-22Aimmune Therapeutics, Inc.$109Research paymentCash or cash equivalentPALFORZIA Biological, ALLERGYA MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS 2021
2021-06-22Aimmune Therapeutics, Inc.$109Research paymentCash or cash equivalentPALFORZIA Biological, ALLERGYA MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS 2021
2021-06-22Aimmune Therapeutics, Inc.$109Research paymentCash or cash equivalentPALFORZIA Biological, ALLERGYA MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS 2021
2021-06-22Aimmune Therapeutics, Inc.$109Research paymentCash or cash equivalentPALFORZIA Biological, ALLERGYA MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS 2021

The latest 200 records of 467.

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

Travis CountyAustin city

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In Austin, TX, county Travis County, TX, state Texas; placed by its city name.

MeasurePlace (city or town)
Austin, TX
County
Travis County, TX
State
Texas
Population B01003979,5391,330,01530,188,424
Population, 2020 census P1961,8551,290,18829,145,505
Median age B0100234.735.635.6
Under 18 B0100118.0%20.2%25.0%
65 and over B0100110.4%11.0%13.4%
Households B11001456,113583,74710,992,816
Foreign born B0500218.7%18.1%17.6%
Median household income B19013$93,658$99,611$78,476
Median family income B19113$128,808$131,256$94,599
Per capita income B19301$62,862$62,607$40,752
Poverty rate B1700112.0%10.9%13.8%
Unemployment rate B230254.7%4.6%5.3%
Civilian labor force B23025617,774799,52415,233,563
Mean commute (minutes) B0801323.725.226.7
Bachelor's degree or higher B1500359.6%56.6%33.8%
Housing units B25001483,071618,23612,128,515
Owner-occupied B2500343.4%52.1%62.6%
Renters B2500356.6%47.9%37.4%
Median home value B25077$555,300$523,000$283,800
Median gross rent B25064$1,729$1,744$1,403
White, not Hispanic B0300247.0%46.9%39.1%
Black B030027.3%7.8%11.9%
Hispanic or Latino B0300231.9%32.6%39.7%
Asian B030029.0%7.8%5.5%
American Indian and Alaska Native B030020.1%0.1%0.1%

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Austin, TX.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.